कंपनी का अवलोकन
Precision BioSciences, Inc. operates as a clinical-stage gene editing entity focused on developing in vivo therapies that facilitate gene edits, specifically insertion, excision, and elimination within the United States. The organization utilizes the ARCUS genome editing platform to execute DNA genome insertion, removal, and repair processes. This enterprise functions within the Healthcare sector and specifically targets the Biotechnology industry, an environment characterized by high research expenditures and long development cycles for novel treatments. The company currently maintains a market capitalization of $170.56 million while generating annual revenue of $34.26 million with a workforce of 68 employees. These financial dimensions indicate that the company is a small-cap biotechnology firm, suggesting a position where capital efficiency is critical for survival and expansion in a capital-intensive industry.
वित्तीय स्वास्थ्य
Precision BioSciences, Inc. reported a trailing twelve-month revenue of $34.26 million, yet it recorded a net income of -$46,609,000 and an EBITDA of -$50,680,000 during the same period. The substantial disparity between positive revenue and significant negative net income reveals a cost structure dominated by high research and development expenses typical of clinical-stage biotechnology firms. The company generated free cash flow of -$21,974,250, which indicates that current operations are burning cash, thereby limiting immediate financial flexibility for external growth without further capital infusion. Despite the negative profit metrics, the company maintains a gross margin of 100.0% and an operating margin of 36.6%, while the profit margin stands at -133.4%. The negative profit margin reflects the heavy operating costs incurred before profitability is realized, whereas the high gross margin suggests efficient production or service delivery models relative to revenue recognition. In terms of leverage, the company holds $115.58 million in cash against $28.81 million in debt, supported by a debt-to-equity ratio of 31.23, which suggests a conservative balance sheet with significant liquidity buffers available to service obligations. Furthermore, a current ratio of 13.32 demonstrates exceptional short-term liquidity, indicating the ability to cover short-term liabilities over 13 times with available current assets. However, the return on equity is -62.7% and the return on assets is -22.4%, metrics that reveal that management effectiveness is currently measured by the preservation of capital rather than the generation of positive returns on invested capital.
मूल्यांकन आकलन
The valuation metrics for Precision BioSciences, Inc. present a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is listed at -1.94, implying that the market expects earnings to remain negative in the near term. The price-to-book ratio stands at 1.73, indicating that the market values the company's equity at a 73% premium over its book value, likely reflecting the potential value of its intellectual property and pipeline. Alternative valuation measures include a price-to-sales ratio of 4.98 and an EV/EBITDA of -1.51, suggesting that investors are pricing the stock based on revenue potential rather than current profitability. The stock has traded between a 52-week low of $3.53 and a 52-week high of $8.82, and without a specific current share price provided in the data, the position relative to this range cannot be precisely calculated. The beta value is 1.09, which signifies that the stock's price volatility is slightly higher than the broader market, moving 9% more than the market index on average.
Growth & Income
Precision BioSciences, Inc. experienced a revenue growth of 5261.1% year-over-year, whereas earnings growth is listed as N/A due to the company's unprofitable status. The absence of positive earnings growth necessitates that investors view revenue expansion as the primary driver of value creation rather than earnings acceleration. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning the organization reinvests all available resources and earnings into its research and development initiatives rather than distributing income to shareholders. This reinvestment strategy is standard for clinical-stage biotechnology companies aiming to advance their therapeutic candidates through clinical trials. The overall growth and income profile is defined by explosive top-line revenue expansion coupled with a complete lack of current profitability and dividend distributions.